

results of the clinical trial showed that the patients who were given chloroquine had a significant reduction in their body temperature. The clinical trial also showed better recovery among the patients who were given chloroquine and hydroxy chloroquine.⁶³⁻⁶⁵ Hydroxychloroquine treatment is significantly associated with viral load reduction as well as disappearance in COVID-19 patients. Further, the outcome is reinforced by azithromycin. The role of lopinavir and ritonavir in the treatment of COVID-19 is uncertain. A potential benefit was suggested by preclinical data, but additional data has failed to confirm it. Tocilizumab is an immunomodulating agent used as adjunct therapy in some protocols based on a theoretical mechanism and limited preliminary data.⁶⁶

15 HOME CARE

Home management may be appropriate for patients with mild infection who can be adequately isolated in the outpatient setting. Management of such patients should focus on prevention of transmission to others, and monitoring for clinical deterioration, which should prompt hospitalization. Interim recommendations on home management of patients with COVID-19 can be found on